Clinical trials: Cancer-associated Thrombosis
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MAGNOLIA (NCT05171075)
- Testing
- Abelacimab, Dalteparin
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 417 people
- Sponsor
- Anthos Therapeutics, Inc.
Cancer-associated Thrombosis
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism…
- Trial name
- CAN-CATCH (NCT06894576)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Ottawa Hospital Research Institute
Cancer, Pulmonary Embolism
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of…
- Conditions
- Cancer, Pulmonary Embolism, Thrombosis
- Trial name
- CATforCAT (NCT06386107)
- Testing
- Thrombin Generation Assay (TGA)
- Where
- 4 sites in France
- Volunteers
- 212 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Cardiovascular Diseases, Arterial Thrombosis
Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and are now approved for various types of cancer. The most common side effects of ICI are immune-related adverse events which can affect any organ or system…
- Conditions
- Cardiovascular Diseases, Arterial Thrombosis, Myocardial Infarction, Stroke
- Trial name
- ITHACA (NCT06519292)
- Testing
- Coronary computed tomography angiography (CCTA) at baseline, Coronary computed tomography angiography (CCTA) after 1 year
- Where
- Netherlands
- Volunteers
- 214 people
- Sponsor
- Hanneke W. M. van Laarhoven
Lymphoma, Thromboembolism
Heparin or Enoxaparin in Patients With Cancer
RATIONALE: Heparin or enoxaparin may be effective in preventing the formation of blood clots in patients with cancer who are undergoing surgery to remove the tumor.
- Conditions
- Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004875
- Testing
- enoxaparin, heparin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Renal Cancer, Kidney Cancer
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden.
- Conditions
- Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
- Trial name
- NEOPAX (NCT05969496)
- Testing
- Axitinib, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Colorado, Denver
Cancer-associated Thrombosis, Thrombocytopenia
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding.
- Trial name
- NCT05255003
- Testing
- Enoxaparin, Dalteparin, Tinzaparin
- Where
- 4 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Tzu-Fei Wang
Venous Thromboembolism, Metastatic Pancreatic Cancer
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
- Conditions
- Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- CATIQ P3 (NCT06861088)
- Testing
- Kinisoquin™
- Where
- 3 sites in United States
- Volunteers
- 480 people
- Sponsor
- Quercis Pharma AG
Thromboembolism, Cancer
Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"
Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis…
- Trial name
- TESEO (NCT03855592)
- Where
- 48 sites in Spain
- Volunteers
- 700 people
- Sponsor
- Fundación Sociedad Española de Oncologia Médica
Venous Thromboembolism, Deep Vein Thrombosis
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
This trial aims at determining if dabigatran is effective in the treatment of malignancy associated VTE. Tolerance and safety of dabigatran will also be assessed.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT03240120
- Testing
- Dabigatran etexilate, Tinzaparin
- Where
- Hong Kong
- Volunteers
- 99 people
- Sponsor
- The University of Hong Kong
Carcinoma, Hepatocellular
Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization
The primary goal of the study is to see if the PET/CT will be able to determine the precise location of the Y-90 particles within the liver and within the tumors.
- Trial name
- PET-Y90 (NCT02848638)
- Volunteers
- 35 people
- Sponsor
- University of Washington
Hepatocellular Carcinoma with PVTT
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
The purpose of this study is to evaluate the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) plus half-dose donafenib (a kind of anti-angiogenesis agents) in advanced hepatocellular carcinoma (BCLC-C…
- Trial name
- DoTH (NCT06646198)
- Testing
- Transjugular intrahepatic portosystemic shunt (TIPS), Donafenib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fei Gao
Myeloproliferative Neoplasm, Splanchnic Vein Thrombosis
MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
A registry of UK patients diagnosed to have splanchnic vein thrombosis and myeloproliferative neoplasm, including isolated mutation of JAK2V617f.
- Conditions
- Myeloproliferative Neoplasm, Splanchnic Vein Thrombosis, JAK2 V617
- Trial name
- MASCOT-R (NCT04994158)
- Testing
- Drugs, procedures
- Where
- United Kingdom
- Volunteers
- 238 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Venous Thromboembolism, Cancer
Cancer Associated Thrombosis : What is the Proportion of Patients Ineligible to a Study as CARAVAGGIO
Venous thromboembolism is a common and fatal disease closely related to cancer. The therapeutic challenge is major due to the high risk of recurrent thromboembolism and bleeding in patients with cancer.
- Trial name
- NCT04846556
- Testing
- data collection
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
Lymphoma, Malignant Solid Neoplasm
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
This phase II trial studies how well xisomab 3G3 works in preventing catheter-associated blood clots (thrombosis) in patients with cancer receiving chemotherapy.
- Conditions
- Lymphoma, Malignant Solid Neoplasm, Plasma Cell Myeloma
- Trial name
- NCT04465760
- Testing
- Xisomab 3G3
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- OHSU Knight Cancer Institute
Treatment of Venous Thromboembolism in Cancer Patients
A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)
This is an observational study in which patient data from the past on venous thromboembolism (VTE) in patients with cancer is studied.
- Trial name
- NCT05150938
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), vitamin K antagonist (VKA)
- Where
- Sweden
- Volunteers
- 5,737 people
- Sponsor
- Bayer
Rivaroxaban, Cancer-associated Thrombosis
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
Rivaroxaban has been developed in the various clinical settings, prevention of venous thromboembolism (VTE)after major orthopedic surgery, prevention of stroke in atrial fibrillation, and in the treatment of acute coronary…
- Conditions
- Rivaroxaban, Cancer-associated Thrombosis, Recurrence, Bleeding
- Trial name
- NCT01989845
- Testing
- Rivaroxaban
- Where
- South Korea
- Volunteers
- 127 people
- Sponsor
- Seoul National University Hospital
Venous Thromboembolism
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
The study is classified as an observational pharmacological study, spontaneous, monocentric, and both retrospective and prospective for adult patients with a diagnosis of venous thromboembolism in the context of neoplasia…
- Trial name
- NCT06714734
- Where
- 2 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)
This is an observational study in which patient data from the past on venous thromboembolism (VTE) in people with cancer is studied. In observational studies, only observations are made without specified advice or interventions.
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism, Cancer
- Trial name
- H2H-OSCAR-US (NCT05461807)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban
- Where
- Germany
- Volunteers
- 2,437 people
- Sponsor
- Bayer